Table 5 Baseline characteristics of study subjects
Variable category | Total (175, 100%) | Reinfected group (26, 14.9%) | Continuously eradicated group (149, 85.1%) | p-value* |
|---|---|---|---|---|
Gender | (N = 175) | (n = 26) | (n = 149) |  |
  Male | (104, 59.4%) | (16, 61.5%) | (88, 59.1%) | 0.75 |
  Female | (71, 40.6%) | (10, 38.5%) | (61, 40.9%) |  |
Age (years) (mean ± SD) | (N = 175) | (n = 26) | (n = 149) |  |
(56.6 ± 9.4) | (57.6 ± 9.4) | (56.4 ± 9.5) | ||
  20-29 | (2, 1.1%) | (0, 0.0%) | (2, 1.3%) | 0.47 |
  30-39 | (4, 2.3%) | (0, 0.0%) | (4, 2.7%) |  |
  40-49 | (34, 19.4%) | (8, 30.8%) | (26, 17.4%) |  |
  50-59 | (61, 34.9%) | (6, 23.1%) | (55, 36.9%) |  |
  60-69 | (62, 35.4%) | (9, 34.6%) | (53, 35.6%) |  |
  70-79 | (11, 6.3%) | (3, 11.5%) | (8, 5.4%) |  |
  80-89 | (1, 0.6%) | (0, 0.0%) | (1, 0.7%) |  |
Clinical diagnosis | (N = 175) | (n = 26) | (n = 149) |  |
  Early gastric cancer | (40, 22.9%) | (7, 26.9%) | (33, 22.1%) | 0.74 |
  Dysplasia | (19, 10.9%) | (4, 15.4%) | (15, 10.1%) |  |
  Peptic ulcer disease | (34, 19.4%) | (7, 26.9%) | (27, 18.1%) |  |
  Chronic gastritis | (82, 46.9%) | (8, 30.8%) | (74, 49.7%) |  |
Histological AG in either antrum or body | (N = 116) | (n = 20) | (n = 96) |  |
  Yes | (67, 57.8%) | (14, 70.0%) | (53, 55.2%) | 0.14 |
  No | (49, 42.2%) | (6, 30.0%) | (43, 44.8%) |  |
Histological IM in either antrum or body | (N = 144) | (n = 21) | (n = 123) |  |
  Yes | (84, 58.3%) | (10, 47.6%) | (74, 60.2%) | 0.20 |
  No | (60, 41.7%) | (11, 52.4%) | (49, 39.8%) |  |
Regimen | (N = 175) | (n = 26) | (n = 149) |  |
  EBMT | (59, 33.7%) | (7, 26.9%) | (52, 34.9%) | 0.23 |
  MEA | (116, 66.3%) | (19, 73.1%) | (97, 65.1%) |  |